Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209462 | 1.00 | CA12 (0.53) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL2230757 | 1.00 | CA12 (0.53) | CA12CA1CA9KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL380910 | 0.99 | CA12 (0.52) | CA12CA1CA9KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5314266 | 0.99 | CA12 (0.52) | CA12CA1CA9KDM4EALDH1A1 | |
| Acetic Acid SCHEMBL30688431 | 0.97 | CA12 (0.53) | CA12CA1CA9KDM4EALDH1A1 | |
| Acetic Acid SCHEMBL5968184 | 0.97 | CA12 (0.53) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL7208677 | 0.93 | CA12 (0.47) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL29543910 | 0.93 | CA12 (0.47) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL7208685 | 0.93 | CA12 (0.47) | CA12CA1CA9KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29805418 | 0.93 | CA12 (0.49) | CA12CA1CA9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12496296-B2 | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases | ALKAHEST, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12493042-B2 | Molecules and methods for iterative polypeptide analysis and processing | WASHINGTON UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4628163-A1 | NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250297300-A1 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | 2025-09-25 | — | — | US | disclosed |
| EP-4610279-A2 | COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | Omeros Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4587763-A1 | DRYER FOR A SPRAY DRYING SYSTEM | Velico Medical, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| US-11453651-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| WO-2022192647-A1 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | GENENTECH, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187491-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE TEXAS A& M UNIVERSITY SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022178128-A1 | SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4031579-A2 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| US-20220178935-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220128546-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-04-28 | — | — | US | disclosed |
| US-20220128567-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT | Sunbird Bio, Inc. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | CA12 4784/4885CA1 4627/4885CA9 3831/4885 |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | AVPR2, AVPR1A, AVPR1B | CA12 4021/4885CA1 3976/4885CA9 3883/4885 |
| US-11453651-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | CA12 4784/4885CA1 4627/4885CA9 3831/4885 |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA9 558/4885 |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA9 558/4885 |
| US-12496296-B2 | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases | LTA4H, LTB4R, LTC4S | CA12 4847/4885CA1 3988/4885CA9 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.